1. Home
  2. CARA vs VRAX Comparison

CARA vs VRAX Comparison

Compare CARA & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CARA
  • VRAX
  • Stock Information
  • Founded
  • CARA 2004
  • VRAX 2013
  • Country
  • CARA United States
  • VRAX United Kingdom
  • Employees
  • CARA N/A
  • VRAX N/A
  • Industry
  • CARA Biotechnology: Pharmaceutical Preparations
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • CARA Health Care
  • VRAX Health Care
  • Exchange
  • CARA Nasdaq
  • VRAX Nasdaq
  • Market Cap
  • CARA 15.1M
  • VRAX 17.2M
  • IPO Year
  • CARA 2014
  • VRAX 2022
  • Fundamental
  • Price
  • CARA $0.31
  • VRAX $1.88
  • Analyst Decision
  • CARA Hold
  • VRAX
  • Analyst Count
  • CARA 4
  • VRAX 0
  • Target Price
  • CARA $1.00
  • VRAX N/A
  • AVG Volume (30 Days)
  • CARA 818.2K
  • VRAX 4.9M
  • Earning Date
  • CARA 11-26-2024
  • VRAX 11-26-2024
  • Dividend Yield
  • CARA N/A
  • VRAX N/A
  • EPS Growth
  • CARA N/A
  • VRAX N/A
  • EPS
  • CARA N/A
  • VRAX N/A
  • Revenue
  • CARA $10,996,000.00
  • VRAX $156,419.00
  • Revenue This Year
  • CARA N/A
  • VRAX $5,169.18
  • Revenue Next Year
  • CARA N/A
  • VRAX $66.97
  • P/E Ratio
  • CARA N/A
  • VRAX N/A
  • Revenue Growth
  • CARA N/A
  • VRAX 1727.11
  • 52 Week Low
  • CARA $0.24
  • VRAX $0.60
  • 52 Week High
  • CARA $1.31
  • VRAX $9.00
  • Technical
  • Relative Strength Index (RSI)
  • CARA 61.61
  • VRAX 44.96
  • Support Level
  • CARA $0.32
  • VRAX $1.92
  • Resistance Level
  • CARA $0.37
  • VRAX $2.50
  • Average True Range (ATR)
  • CARA 0.03
  • VRAX 0.22
  • MACD
  • CARA 0.00
  • VRAX -0.01
  • Stochastic Oscillator
  • CARA 64.22
  • VRAX 15.41

About CARA Cara Therapeutics Inc.

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Share on Social Networks: